| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d0fc2b70675ee19bd5fc464f5ae9061 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70596 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2021-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1734b60e1151a239987ab5e1cac7d8f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b50bc2a46f012b5755805c0ce514cd6b |
| publicationDate |
2021-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021225378-A1 |
| titleOfInvention |
Pd-1 variants having increased pd-l1 affinity |
| abstract |
The present invention relates to PD-1 variants having minimal mutations for enhancing binding ability to PD-L1. The PD-1 variants of the present invention have fewer mutations than existing PD-1 and PD-1 mutants and have significantly increased binding ability to PD-L1 compared to the existing mutants, thereby solving the problem of immunogenicity. In addition, since these mutants are very small-sized proteins as compared to existing antibody therapeutic agents, PD-1/PD-L1 binding of tumors and immune cells in a tumor microenvironment can be effectively inhibited, and since the problem of low binding ability of PD-L1 to existing PD-1 has been solved, the therapeutic effect thereof as a therapeutic agent can be significantly improved. These mutants can also be used as an imaging agent for detecting the expression level of PD-L1. |
| priorityDate |
2020-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |